SCHEMBL10183285

SCHEMBL10183285

CCOC(=O)N1CC(n2cnc3cnc(C(C)(C)C)cc32)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
HPGD P15428 5/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
GAA P10253 1/20 0.46
NPC1 O15118 1/20 0.43
USP2 O75604 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 2/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10233463 0.91 ALDH1A1 (0.45) ALDH1A1HPGDMEN1KMT2AGAA
SCHEMBL10183293 0.86 MAP3K12 (0.36) ALDH1A1HPGDMEN1KMT2AGAA
SCHEMBL10183257 0.85 IDO1 (0.37) ALDH1A1GAAHSD17B10IDO1TP53
SCHEMBL10183166 0.81 HCAR1 (0.47)
SCHEMBL10183159 0.80 JAK1 (0.35) JAK2JAK1TYK2JAK3IDO1
SCHEMBL10183230 0.78 GLRA3 (0.35) GAAUSP2SMN1; SMN2LMNAHTT
SCHEMBL10183281 0.77 SYK (0.35) ALDH1A1HPGDGAALMNAJAK2
SCHEMBL10183626 0.76 EGFR (0.40) ALDH1A1HPGDGAANPC1USP2
SCHEMBL10183263 0.75 GLRA3 (0.41) ALDH1A1HPGDMEN1KMT2AGAA
SCHEMBL10183244 0.75 IDO1 (0.35) ALDH1A1HPGDMEN1KMT2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF ALDH1A1 1934/4885HPGD 2536/4885MEN1 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.